Senores Q1 revenue jumps 36% to ₹180 cr, profit up 56%
Regulated markets lead with 42% growth as ANDA portfolio expands to 58 products; EBITDA surges 87% to ₹54 crore.
— 5 earlier stories on Senores Pharmaceuticals Ltd. →What's new
- Revenue of ₹180 cr, up 36% YoY; net profit ₹31 cr, up 56%.
- EBITDA surged 87% to ₹54 cr, outpacing revenue growth.
- Regulated markets segment grew 42% to ₹127.8 cr, driven by 58 ANDAs.
Why this matters
Senores is delivering consistent double-digit growth, with regulated markets now accounting for over 70% of revenue. The Baroda USFDA plant ramp-up adds further scale potential, though execution over the next 12-18 months will determine if margins remain strong.
What we're watching
- How quickly the Baroda plant scales to full capacity.
- Timeline for commercializing the remaining 35 ANDAs.
- Whether EBITDA margins can hold above 30%.
The full read
Senores Pharmaceuticals posted a strong first quarter for fiscal 2027, with revenue climbing 36% to ₹180 crore and net profit rising 56% to ₹31 crore. The regulated markets segment (the US and Canada) led the charge with 42% growth to ₹127.8 crore, powered by 58 approved ANDAs, of which 23 are now commercial. EBITDA surged 87% to ₹54 crore, pushing margins higher. Emerging markets also turned cash-flow positive on 30% revenue growth. Managing Director Swapnil Shah pointed to portfolio expansion, manufacturing efficiencies, and the ramp-up of the new Baroda USFDA plant as drivers. That facility should add more heft over the next year. At a market cap of ₹5,840 crore and a P/E of 50.6, the valuation already bakes in this trajectory. The next test is margin durability as the plant scales.
Questions answered
- What drove the 36% revenue growth in Q1?
- The regulated markets segment (US & Canada) grew 42% to ₹127.8 crore, supported by an expanded ANDA portfolio of 58 approved products, 23 of which are commercialized. Emerging markets also contributed 30% growth to ₹37.6 crore.
- How did profitability compare to revenue growth?
- EBITDA rose 87% to ₹54 crore, outpacing revenue growth significantly, indicating improved operating leverage. Net profit increased 56% to ₹31 crore.
- What is the significance of the Baroda USFDA plant?
- The newly acquired plant is expected to scale over the next 12-18 months, adding manufacturing capacity and potentially boosting revenues. It was highlighted by management as a key growth driver.
- Is this result in line with market expectations?
- The company's prior guidance suggested a similar trajectory, and the numbers are consistent with the strong growth trend seen in previous quarters. The market cap of ₹5,840 crore implies a trailing P/E of ~50, reflecting high growth expectations.
Story so far
All notes on SENORES →- 27 Jul 2026 · 3:49 PM IST Senores Q1 revenue jumps 36% to ₹180 cr, profit up 56%
- today Senores Pharma targets 50-60% PAT growth after Q1 beat
- today Senores delays Atlanta plant, redirects ₹65 cr of IPO funds
- today Senores Q1 profit rises 56% on regulated markets growth
- today Senores' Q1: Revenue up 36%, profit up 56% — in line with guidance